Pemphigus vulgaris following second dose of mRNA-(Pfizer-BioNTech) COVID-19 vaccine.

Agharbi, Fatima-Zahra; Basri, Ghita; Chiheb, Soumia

Agharbi, Fatima-Zahra; Basri, Ghita; Chiheb, Soumia.

Agharbi FZ; Department of Dermatology, Sheikh Khalifa Hospital, Faculty of Medicine, Mohamed VI University of Health Sciences, Casablanca, Morocco.
Basri G; Department of Dermatology, Sheikh Khalifa Hospital, Faculty of Medicine, Mohamed VI University of Health Sciences, Casablanca, Morocco.
Chiheb S; Department of Dermatology, Sheikh Khalifa Hospital, Faculty of Medicine, Mohamed VI University of Health Sciences, Casablanca, Morocco.

Dermatol Ther ; 35(10): e15769, 2022 10.

Article in English | MEDLINE | ID: covidwho-1992772

Subject(s)

COVID-19 Vaccines; COVID-19; Pemphigus; COVID-19/prevention & control; COVID-19 Vaccines/adverse effects; Humans; Immunoglobulin G; Pemphigus/chemically induced; Pemphigus/diagnosis; RNA, Messenger

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pemphigus / COVID-19 Vaccines / COVID-19 Type of study: Diagnostic study Topics: Vaccines Limits: Humans Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Dth.15769

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google